Uploaded April 2026 | Updated September 2026, 2 weeks ago
Finding the right "key" for a biological "lock" takes months of trial and error, but the Rapid Automated Binder Identification Technology (RABIT) platform, developed by the Center for Development of Therapeutics (CDoT) at the Broad Institute, has found a way to speed up the process. The RABIT platform combines high tech automation and chemical biology to test billions of potential binders to specific disease targets with incredible precision, without the need for living cells. Using these automated robots to do the heavy lifting empowers scientists to drive faster and more cost-effective initiatives for next generation therapeutics.
Finding the right "key" for a biological "lock" takes months of trial and error, but the Rapid Automated Binder Identification Technology (RABIT) platform, developed by the Center for Development of Therapeutics (CDoT) at the Broad Institute, has found a way to speed up the process. The RABIT platform combines high tech automation and chemical biology to test billions of potential binders to specific disease targets with incredible precision, without the need for living cells. Using these automated robots to do the heavy lifting empowers scientists to drive faster and more cost-effective initiatives for next generation therapeutics.
